CMS' 2012 Budget Looks To Biosimilars, Ban On Brand/Generic Deals To Offset Costs
This article was originally published in The Pink Sheet Daily
Executive Summary
The two legislative proposals contained in the budget seem unlikely to pass in the current Congress.